Clinical Trial Update: Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update on cardiac T2* in beta-thalassemia patients treated with deferasirox; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis | Conditions: Beta-thalassemia, Iron Overload | Phase 2 | Status: COMPLETED | Results posted: 2021-06-07